AstraZeneca loses appeal at Court of Justice

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

AstraZeneca loses appeal at Court of Justice

Pharma companies in Europe should reconsider their antitrust risk following a ruling by the Court of Justice this morning

In a relatively straightforward decision, the Court dismissed AstraZeneca's appeal of a General Court ruling that had in turn largely upheld a finding by the European Commission in 2005.

That finding imposed a fine of €60 million on AstraZeneca (later reduced to €52.5 million by the General Court) for infringing competition rules. The Commission said the company's patent and SPC strategies, designed to limit competition from generic rivals, amounted to an abuse of its dominant position.

The Court of Justice also rejected a cross-appeal by the Commission in relation to the reduced level of fine imposed on AstraZeneca.

For the full background on the case, see Managing IP's briefing.

"The Commission will be delighted with the endorsement to its approach; innovative pharma less so. The pharmaceutical industry is now subject to a set of onerous but not fully clear obligations," commented Marie Manley, head of Bristows' Pharmaceutical Regulatory team.

John Cassels at Field Fisher Waterhouse identified three key lessons from the case:

  • There is a trend towards narrower market definition which means that companies may be wrong when they consider themselves too small to be dominant;

  • First movers with patents face a risk of dominance, even in sectors characterised by innovation; and

  • It appears to impose active obligations on dominant companies, for example to disclose their interpretation of legal provisions upon which they rely when applying for IP rights or undertaking a course of action

Pat Treacy, head of Bristows' competition team, argued that the impact goes beyond the pharma sector. "All companies which may be dominant now have an obligation to conduct themselves transparently when dealing with the public authorities. AstraZeneca has been penalised for making arguments that favoured its position when the issue was legally unclear," she said.

For background on the case, see Managing IP's guide to the case.

The full text of the decision can be seen here.

more from across site and SHARED ros bottom lb

More from across our site

The firm has brought in former Weil IP leaders Doug Lumish and Jeff Homrig as it looks to deepen its patent, trade secrets and ITC bench
Bird & Bird helps GSK score a major injunction as the battle to become the UPC’s busiest division tightens, and overall filings reach a new monthly high
CEO Annette Bach explains how the Danish IP consultancy plans to build on its 65% profit growth while keeping external investment off the table for now
Belgian attorneys have revived fax systems to protect clients’ filing rights, while uncertainty over exposed patent data has left firms struggling to answer questions about the breach
In his first interview since leaving Weil Gotshal & Manges, Chris Henry explains why he returned to Latham and how he plans to bolster its tech disputes offering
As GTA VI underlines the extraordinary value of gaming franchises, lawyers at Clifford Chance say investors need to know the IP behind their next deal can deliver the growth they are paying for
As ‘big law’ invests in IP litigation, trial firms are emerging as a valuable source of seasoned courtroom talent
Six hires across the IP spectrum reflect Orrick’s efforts to better serve tech clients across the IP lifecycle
David Stone, partner at White & Case, argues that the government’s planned reforms will modernise and futureproof UK design law, but leave two of the thorniest problems unresolved
Max Scott will join the firm’s IP transactions group in California, becoming the latest Weil IP partner to secure their future
Gift this article